Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|October 31, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-11-06-2019
- Volume 14
- Issue 11
New Zippered Lab Coat from Kimberly-Clark Professional Offers Reduced Risk of Contamination
In response to customer requests for a more secure closure, the company equipped the new lab coat with a nylon zipper and no-pocket design, rather than the typical snap design, which runs the risk of contamination to people and processes.
Advertisement
On Oct. 25, 2019, Kimberly-Clark Professional, a personal care corporation headquartered in Irving, TX, introduced the Kimtech A8 Zippered Lab Coat for liquid and particle protection for ISO 7 and 8 or higher cleanroom environments.
In response to customer requests for a more secure closure, the company equipped the new lab coat with a nylon zipper and no-pocket design, rather than the typical snap design, which runs the risk of contamination to people and processes because of gaps between the closures and the possibility of the snaps falling off, according to a company press release.
The lab coat is available in sizes small to 6XL with anti-static three-layer spunbond meltblown spunbond fabric, a mandarin collar for added protection, and soft knit cuffs. It can also be recycled through The RightCycle Program, a recycling program for non-hazardous lab, cleanroom, and industrial waste.
Source:
Articles in this issue
almost 7 years ago
How Best to Select a Quality Cell-Line Sourcealmost 7 years ago
Reviewing the Basic Principles of Dissolution Testingalmost 7 years ago
New 2D Code Reader by Micronic Guarantees Greater Accuracyalmost 7 years ago
TetraScience Receives Strategic Investment from Watersalmost 7 years ago
Frontage Expands Bioanalytical Capacity and Capabilitiesalmost 7 years ago
Integra Offers Clear Advantage Product for NGS Library Preparationabout 7 years ago
MilliporeSigma Launches ADC Express Servicesabout 7 years ago
Novartis Collaborates with Microsoft for AI Innovation LabAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5